<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489449</url>
  </required_header>
  <id_info>
    <org_study_id>PEPCAD NSTEMI</org_study_id>
    <nct_id>NCT01489449</nct_id>
  </id_info>
  <brief_title>Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction</brief_title>
  <acronym>PEPCADNSTEMI</acronym>
  <official_title>Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present trial is to assess the efficacy of the standalone use of SeQuent(R)
      Please coated balloon compared to a bare metal stent (BMS) in patients with NSTEMI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present trial is to assess the efficacy of the standalone use of SeQuent(R)
      Please coated balloon compared to a bare metal stent (BMS) in patients with NSTEMI. Primary
      efficacy endpoint will be MACE (cardiac mortality, reinfarction, and target lesion
      revascularization) after 9 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 23, 2022</completion_date>
  <primary_completion_date type="Actual">June 23, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>9 months</time_frame>
    <description>MACE means the occurence of cardiac death, reinfarction, or target lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (ARC</measure>
    <time_frame>9 months, 3 years, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (cardiac and non-cardiac)</measure>
    <time_frame>9 months, 3 years, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinfarction</measure>
    <time_frame>9 months, 3 years, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization</measure>
    <time_frame>9 months, 3 years, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel revascularization</measure>
    <time_frame>9 months, 3 years, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any revascularization</measure>
    <time_frame>9 months, 3 years, 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>NSTEMI</condition>
  <arm_group>
    <arm_group_label>Stent</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Stent Implantation (DES or BMS), no further treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;DEBonly&quot; strategy: treatment with drug coated balloon, additional spot-stenting in case of severe dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent</intervention_name>
    <description>bare metal stent implantation, any bare metal stent is allowed from different companies</description>
    <arm_group_label>Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SeQuent(R) Please coated balloon</intervention_name>
    <description>Angioplasty with Drug coated balloon (DCB)</description>
    <arm_group_label>DCB</arm_group_label>
    <other_name>SeQuent(R) Please</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NSTEMI with

          -  Ischemic symptoms (angina pectoris) &gt; 30 minutes

          -  Last symptoms within 72 hours before randomization

          -  Positive cardiac troponin T, I, or hs-Troponin above 99th percentile

          -  age &gt; 18 years

          -  Identifiable culprit lesion without angiographic evidence of large thrombus with
             intended early PCI (treatment of up to two lesions allowed)

        Exclusion Criteria:

          -  Cardiogenic shock

          -  ST-elevation myocardial infarction

          -  No identifiable culprit lesion, Indication for acute bypass surgery

          -  Comorbidity with limited life expectancy &lt; 9-12 months

          -  Contraindication for treatment with heparin, ASA and thienopyridines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Scheller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg/Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 27, 2011</study_first_submitted>
  <study_first_submitted_qc>December 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2011</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug coated balloon</keyword>
  <keyword>NSTEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

